• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Flora Growth Appoints Former Amazon Executive Tim Leslie to Its Board of Directors and Names CEO Luis Merchan Chairman

    3/17/22 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FLGC alert in real time by email
    • Flora Growth's CEO Luis Merchan is named Chairman of the Board of Directors.
    • Tim Leslie, Chairman of Flora's Advisory Board, will join the Flora Board of Directors and audit committee.
    • Changes to the Board of Directors signal the Company's move toward becoming a U.S.-based issuer and will support Flora's growth into new international markets.

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, announced today changes to its Board of Directors (the "Board") including the appointment of CEO Luis Merchan as Chairman of the Board as well as the addition of industry veteran Tim Leslie to the Board and audit committee. Merchan has replaced Bernie Wilson as Chairman of the Board. Wilson will remain in an advisory capacity for the remainder of 2022 and will provide strategic guidance on capital markets and international expansion. The changes to the Board will further position Flora as a U.S.-based issuer and is expected to increase the Company's access to U.S-based investment.

    Flora Chairman and CEO Luis Merchan has been focused on expanding the Company's reach within the United States and abroad. Through his leadership, Flora has moved from the development stage to a full-scale international distributor and house of brands with operations in more than 12 countries. He has been pivotal in completing recently announced M&A transactions with leading hardware manufacturer Vessel and highly regarded wellness company JustCBD, solidifying the path to rapid growth.

    "I am honored that our Board has entrusted me with this role, and I believe it is a testament to what we have built together thus far," said Flora Growth CEO and newly appointed Chairman of the Board Luis Merchan. "Our Board has been incredibly supportive to date while always ensuring business decisions are in the best interest of our shareholders - and I am looking forward to continuing to work closely with them in this role."

    A Yale Law graduate, Tim Leslie has a strong pedigree of success, working with scaling companies including his two decades at Amazon. Leslie has been Chairman of the Company's Advisory Board since the beginning of 2022, where he has utilized his years of experience as CEO of Leafly and as an Amazon executive to help counsel Flora's leadership team. As Flora continues its rapid, global expansion, Leslie will play a critical role in navigating this hyper-growth phase. In addition to his role as board member, Leslie will also join the Company's audit committee.

    These appointments come as former Chairman of the Board, Bernie Wilson, steps down from his role and transitions to an advisory capacity to provide Merchan and the Board with strategic counsel, leveraging his insights and tenure in capital markets. "We want to thank Bernie for his commitment to the growth of Flora during this formative time for our company and look forward to continuing to work with him as we continue to grow," added Merchan.

    About Flora Growth Corp.

    Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that is designed to deliver one of the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. Visit www.floragrowth.com or follow @floragrowthcorp on social [media] for more information.

    Cautionary Statement Concerning Forward-Looking Statements

    This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: the size of markets for cannabis and cannabis products; the collaboration with third parties; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, or the forward-looking events discussed in this document and other statements made from time to time by us or our representatives not occurring, except as may be required by applicable law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005405/en/

    Get the next $FLGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLGC

    DatePrice TargetRatingAnalyst
    11/25/2024$4.00Buy
    Aegis Capital
    10/13/2021$10.00Buy
    Roth Capital
    6/23/2021$6.00Buy
    MKM Partners
    More analyst ratings

    $FLGC
    SEC Filings

    See more
    • SEC Form S-3 filed by Flora Growth Corp.

      S-3 - Flora Growth Corp. (0001790169) (Filer)

      5/14/25 4:02:08 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Flora Growth Corp.

      10-Q - Flora Growth Corp. (0001790169) (Filer)

      5/13/25 4:56:00 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Flora Growth Corp.

      D - Flora Growth Corp. (0001790169) (Filer)

      5/8/25 7:36:37 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital initiated coverage on Flora Growth with a new price target

      Aegis Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $4.00

      11/25/24 8:07:10 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital initiated coverage on Flora Growth with a new price target

      Roth Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $10.00

      10/13/21 9:00:51 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MKM Partners initiated coverage on Flora Growth with a new price target

      MKM Partners initiated coverage of Flora Growth with a rating of Buy and set a new price target of $6.00

      6/23/21 5:36:01 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Starke Clifford bought $6,455 worth of shares (6,795 units at $0.95), increasing direct ownership by 13,324% to 6,846 units (SEC Form 4)

      4 - Flora Growth Corp. (0001790169) (Issuer)

      9/17/24 10:17:39 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wolkin Harold bought $24,255 worth of shares (25,000 units at $0.97) (SEC Form 4)

      4 - Flora Growth Corp. (0001790169) (Issuer)

      9/11/24 5:43:51 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Starke Clifford bought $48 worth of shares (51 units at $0.95), increasing direct ownership by 0.01% to 474,046 units (SEC Form 4)

      4 - Flora Growth Corp. (0001790169) (Issuer)

      9/6/24 5:25:10 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLGC
    Leadership Updates

    Live Leadership Updates

    See more

    $FLGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $FLGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flora Growth Corp. Appoints Clifford Starke as Chief Executive Officer and Dany Vaiman as Chief Financial Officer; Regains Compliance with NASDAQ Minimum Bid Requirement

      Fort Lauderdale, Florida--(Newsfile Corp. - June 27, 2023) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a consumer-packaged goods leader serving all 50 states with 15,000+ points of distribution around the world and a pharmaceutical distributor in 28 countries, announced today that Clifford Starke has been appointed as Chief Executive Officer to lead its global operations and Dany Vaiman has been appointed as Chief Financial Officer. Mr. Starke, who previously served as President of the Company, takes over for Hussein Rakine, who resigned as CEO but will remain on the Company's Board of Directors. Mr. Rakine expressed his confidence in the appointment, stating, "Clifford's

      6/27/23 4:05:00 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flora Growth Corp. Announces the Appointment of Hussein Rakine as CEO and Member of the Board of Directors

      Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company") a leading cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its board of directors (the "Board") accepted the resignation of Luis Merchan as Chairman of the Board and the Company's Chief Executive Officer (CEO). To fill the vacancies created by Mr. Merchan's resignation, the Board has appointed JustCBD founder, Hussein Rakine, as CEO and member of the board of directors. Of the appointment, former-Chairman and CEO, Luis Merchan said, "At Flora we have consistently placed human capital as a critical part of our M&A strategy. That's why today we are honored to have the former foun

      4/18/23 4:05:00 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CBD Oil Market to Hit Nearly US$137 Billion by 2029

      FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 23, 2022 /PRNewswire/ -- The CBD oil market is expected to witness an astounding CAGR of 38.90% from 2021 until 2029, climbing from $9.86 billion to $136.64 billion. There are several reasons behind the projected growth such a growing number of CBD-infused skincare products, increased use of THC and CBD in pain management and treatment, rising sales in both retail stores and online, expanding research, and increasing demand for ingestible products. Governments around the world have also begun opening up more doors for CBD, with a recent Health Canada report suggesting legal framework to broaden retail CBD sales across

      8/23/22 8:50:00 AM ET
      $CGC
      $CRON
      $FLGC
      $OGI
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

      SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

      12/17/24 8:02:53 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

      SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

      12/17/24 8:01:40 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Flora Growth Corp.

      SC 13G/A - Flora Growth Corp. (0001790169) (Subject)

      11/14/24 2:24:54 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flora Growth Corp. Closes Acquisition of Australian Vaporizers

      Fort Lauderdale, Florida--(Newsfile Corp. - June 5, 2024) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company") has entered into a share purchase agreement (the "Agreement") to acquire of all of the issued and outstanding shares of Australian Vaporizers Pty Limited ("Australian Vaporizers") in exchange for 550,000 Flora common shares, valued at $0.7 million based on the closing price of Flora's common shares on June 3, 2024, subject to working capital adjustments. The transaction closed on June 4, 2024. Australian Vaporizers was founded in 2010 and has become one of the largest online retailers of vaporizers, hardware, and accessories in Australia. It is an online expert for aromathe

      6/5/24 9:20:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifeist Sells Australian Vapes

      TORONTO, June 05, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV:LFST) (FRANKFURT: M5B) (OTC:LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced the sale of Australian Vaporizers Pty Ltd. ("Aussie Vapes"), its wholly owned Australian subsidiary to Flora Growth Corp. (NASDAQ:FLGC) ("Flora"), a U.S.-based consumer-packaged goods and pharmaceutical distributor serving all 50 states and 28 countries. The sale was completed through a share purchase agreement (the "SPA") entered into between Lifeist, as vendor, and Flora Growth Corp, as purchaser, purs

      6/5/24 7:00:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TSX Venture Exchange Stock Maintenance Bulletins

      VANCOUVER, BC, June 4, 2024 /CNW/ - TSX VENTURE COMPANIES BULLETIN V2024-1678 CEAPRO INC. ("CZO")BULLETIN TYPE: Plan of Arrangement, Remain Halted, DelistBULLETIN DATE: June 4, 2024TSX Venture Tier 2 Company  TSX Venture Exchange (the "Exchange") has accepted for filing documentation in connection with an arrangement agreement dated December 14, 2023, as amended on January 16, 2024, between Ceapro Inc. ("Ceapro") and Aeterna Zentaris Inc. ("Aeterna"), pursuant to which Aeterna acquired all of the issued and outstanding common shares of Ceapro by way of a plan of arrangement under the Canada Business Corporations Act (the "Arrangement"). Under the terms of the Arrangement, Ceapro shareholder

      6/4/24 11:24:00 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLGC
    Financials

    Live finance-specific insights

    See more
    • Flora Growth Sets Third Quarter 2022 Conference Call for November 28, 2022, at 4:30 P.M. ET

      Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, will host its third quarter 2022 earnings call via webcast on Monday, November 28 at 4:30 p.m. ET. During the webcast, Flora management will deliver financial and operational results for the third quarter ended September 30, 2022, and provide updates on Flora's commercial wholesale operations, house of brands and life sciences division strategies. Following the webcast, Flora management will open the call to analysts, media and investors in a Q&A format. Live Webcast Details Date: Monday, November 28, 2022 Time: 4:30 p.m. ET

      11/21/22 7:05:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flora Growth to Host Webcast Discussing M&A Activity and International Market Opportunities - Wednesday, October 26, 2022

      Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that the Company will be hosting an analyst call on Wednesday, October 26, 2022, at 02:00 p.m. EST via webcast to discuss Flora Growth's recent M&A activity and strategic growth opportunities. The conference call and live webcast will invite analysts to pose questions to Flora and Franchise Global Health's leadership teams regarding the recent announcement of the definitive agreement of acquisition between the two companies and the opportunities within the cannabis industry on the global stage. To access this ca

      10/25/22 7:05:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flora Growth Awarded Best M&A Deal at Benzinga Cannabis Capital Conference

      Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that the Company received the Best M&A Deal award at Benzinga's 2022 Cannabis Capital Conference in Chicago. "We are honored to receive the award for Best M&A Deal at the Benzinga Cannabis Capital Conference, which recognizes our strategic M&A objectives including acquiring products, expertise, expanding distribution, and customers," said Luis Merchan, Chairman and CEO of Flora. Flora completed the acquisition of JustCBD in February 2022, and it immediately offered the Company an established CPG brand with a por

      9/13/22 7:05:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Woo Edward was granted 50,000 shares, increasing direct ownership by 59% to 134,698 units (SEC Form 4)

      4 - Flora Growth Corp. (0001790169) (Issuer)

      12/17/24 10:22:07 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wolkin Harold

      4 - Flora Growth Corp. (0001790169) (Issuer)

      12/17/24 10:19:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO Vaiman Dany

      4 - Flora Growth Corp. (0001790169) (Issuer)

      12/17/24 10:01:07 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care